Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Haemolytic anaemia triggered by antitumoural “biological agents” and immunotherapies with monoclonal antibodies: short review of the literature

Haemolytic anaemia triggered by antitumoural “biological agents” and immunotherapies with... In the last decade, many novel immunomodulating therapies and “biologicals”, usually acting as signal transduction inhibitors, came into routine therapy in cancer. Mostly, these substances are well tolerated, and there is a typical spectrum of common side effects to be considered with these therapies. A rather rarely seen toxic effect associated with the administration of these agents is haemolytic anaemia (HA). Here, we shortly summarize current knowledge on HA potentially triggered by these substances. Furthermore, an impressive case of myelodysplastic syndrome with 5q deletion which received lenalidomide and developed autoimmune haemolytic anaemia (AIHA) is presented. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Haemolytic anaemia triggered by antitumoural “biological agents” and immunotherapies with monoclonal antibodies: short review of the literature

Loading next page...
 
/lp/springer-journals/haemolytic-anaemia-triggered-by-antitumoural-biological-agents-and-ei9ugnjWkR

References (30)

Publisher
Springer Journals
Copyright
Copyright © 2010 by Springer
Subject
Medicine & Public Health; Medicine/Public Health, general ; Oncology
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-010-0174-y
Publisher site
See Article on Publisher Site

Abstract

In the last decade, many novel immunomodulating therapies and “biologicals”, usually acting as signal transduction inhibitors, came into routine therapy in cancer. Mostly, these substances are well tolerated, and there is a typical spectrum of common side effects to be considered with these therapies. A rather rarely seen toxic effect associated with the administration of these agents is haemolytic anaemia (HA). Here, we shortly summarize current knowledge on HA potentially triggered by these substances. Furthermore, an impressive case of myelodysplastic syndrome with 5q deletion which received lenalidomide and developed autoimmune haemolytic anaemia (AIHA) is presented.

Journal

memo - Magazine of European Medical OncologySpringer Journals

Published: Apr 14, 2010

There are no references for this article.